CLA-2-30:OT:RR:NC:N3:138
Mr. Pradeep Shah
Zydus Pharmaceuticals USA Inc.
73 Route 31 North
Pennington, NJ 08534
RE: The tariff classification of Leflunomide Tablets and Chlorthalidone Tablets in dosage form, from India
Dear Mr. Shah:
In your letter dated March 21, 2019, you requested a tariff classification ruling.
Leflunomide, imported in 10 mg and 20 mg tablets, is an immunosuppressive disease-modifying antirheumatic drug (DMARD). It is indicated for the treatment of active rheumatoid arthritis (RA) in adults.
Chlorthalidone, imported in 25 mg and 50 mg tablets, is a diuretic medication. It is indicated for the treatment of hypertension (high blood pressure) and edema (fluid retention).
The applicable subheading for Leflunomide tablets in dosage form will be 3004.90.9215, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Antineoplastic and immunosuppressive medicaments.” The rate of duty will be free.
The applicable subheading for Chlorthalidone tablets in dosage form will be 3004.90.9265, HTSUS, which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in the forms of packings for retail use: Other: Other: Other: Preparations primarily affecting the electrolytic, caloric or water balance: Diuretics.” The rate of duty will be free.
Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177).
A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected].
Sincerely,
Steven A. Mack
Director
National Commodity Specialist Division